Literature DB >> 31427258

An Appendix of Radionuclides Used in Targeted Alpha Therapy.

Maryline G Ferrier1, Valery Radchenko2.   

Abstract

Keywords:  Radiation; actinium-225; astatine-211; bismuth-212/213; radium-223/224; thorium-226/227

Mesh：

Substances：

Year:  2019        PMID： 31427258     DOI： 10.1016/j.jmir.2019.06.051

Source DB:  PubMed          Journal:  J Med Imaging Radiat Sci        ISSN： 1876-7982


× No keyword cloud information.
  6 in total

1.  Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand 212Pb-NG001.

Authors:  Vilde Yuli Stenberg; Anna Julie Kjøl Tornes; Hogne Røed Nilsen; Mona-Elisabeth Revheim; Øyvind Sverre Bruland; Roy Hartvig Larsen; Asta Juzeniene
Journal:  Cancers (Basel)       Date:  2022-06-03       Impact factor: 6.575

Review 2.  Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest
Journal:  Pharmaceutics       Date:  2020-12-31       Impact factor: 6.321

Review 3.  Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges.

Authors:  Suliman Salih; Ajnas Alkatheeri; Wijdan Alomaim; Aisyah Elliyanti
Journal:  Molecules       Date:  2022-08-16       Impact factor: 4.927

4.  Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.

Authors:  Florian Rosar; Jonas Krause; Mark Bartholomä; Stephan Maus; Tobias Stemler; Ina Hierlmeier; Johannes Linxweiler; Samer Ezziddin; Fadi Khreish
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

5.  Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets.

Authors:  Matthew J O'Hara; Anthony J Krzysko; Donald K Hamlin; Yawen Li; Eric F Dorman; D Scott Wilbur
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

6.  Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.

Authors:  Matteo Bauckneht; Rita Lai; Francesca D'Amico; Alberto Miceli; Maria Isabella Donegani; Cristina Campi; Daniela Schenone; Stefano Raffa; Silvia Chiola; Francesco Lanfranchi; Sara Elena Rebuzzi; Elisa Zanardi; Malvina Cremante; Cecilia Marini; Giuseppe Fornarini; Silvia Morbelli; Michele Piana; Gianmario Sambuceti
Journal:  Ann Nucl Med       Date:  2022-01-19       Impact factor: 2.668
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.